Effect of continuous versus episodic amiodarone treatment on quality of life in persistent atrial fibrillation

Europace

Volumn 12, Issue 6, 2010, Pages 785-791

  Ahmed, Sheba ^a   Ranchor, Adelita V ^b   Crijns, Harry J G M ^c   Van Veldhuisen, Dirk J ^a   Van Gelder, Isabelle C ^a,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Northern Center for Healthcare Research   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

Amiodarone; Atrial fibrillation; Quality of life

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN;

AGED; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECURRENT DISEASE; SHORT FORM 36; SINUS RHYTHM; THYROID DISEASE; TREATMENT RESPONSE;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 77953007969     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euq049     Document Type: Article

References (17)

1. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al.. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2006;27:1979-2030. (Pubitemid 44313588)
2. Neuberger HR, Mewis C, Van Veldhuisen DJ, Schotten U, Van Gelder IC, Allessie MA et al.. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007;28:2568-2577
3. Van Den Berg MP, Hassink RJ, Tuinenburg AE, van Sonderen EF, Lefrandt JD, De Kam PJ et al.. Quality of life in patients with paroxysmal atrial fibrillation and its predictors: importance of the autonomic nervous system. Eur Heart J 2001; 22:247-253
4. Hagens VE, Ranchor AV, Van Sonderen E, Bosker HA, Kamp O, Tijssen JG et al.. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 2004;43:241-247 (Pubitemid 38201151)
5. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R et al.. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-1068
6. Dorian P, JungW, Newman D, Paquette M, Wood K, Ayers GM et al.. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 2000; 36:1303-1309
7. Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J Cardiovasc Electrophysiol 2008;19:762-768
8. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al.. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-920
9. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL et al.. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-1872
10. Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL et al.. Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. J Am Med Assoc 2008;300:1784-1792
11. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 48th ed., revised ed. New York, NY: Academic Press. 2009.
12. Dorian P, Paquette M, Newman D, Green M, Connolly SJ, Talajic M et al.. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J 2002;143:984-990
13. Channer KS, Birchall A, Steeds RP, Walters SJ, Yeo WW, West JN et al.. A randomized placebo-controlled trial of pre-treatment and short- or long-term maintenance therapy with amiodarone supporting DC cardioversion for persistent atrial fibrillation. Eur Heart J 2004;25:144-150
14. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L et al.. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med 2008;359:999-1008.
15. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A et al.. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007; 357:987-999
16. Davy JM, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D et al.. Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J 2008;156:527-529
17. Singh SN, Tang XC, Singh BN, Dorian P, Reda DJ, Harris CL et al.. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. J Am Coll Cardiol 2006;48:721-730